Villars V V, Jones T C
Department of Clinical Research, Sandoz Pharma Ltd, Basel, Switzerland.
Br J Dermatol. 1992 Feb;126 Suppl 39:61-9. doi: 10.1111/j.1365-2133.1992.tb00013.x.
Terbinafine (Lamisil) is an antifungal drug, belonging to a class of drugs called the allylamines, which has recently become available for clinical use. This is a report of four special features which emerged during evaluation of the systemic use of orally administered terbinafine in the treatment of 2500 patients during the last 5 years. These features include: (i) distribution of terbinafine in skin, hair and nail tissue; (ii) use in short-duration treatment of chronic tinea pedis and onychomycosis; (iii) use in patients with serious infections often associated with local or generalized immunological defects; and (iv) tolerability and safety of the drug. The diffusion of terbinafine into thickened, chronically infected tissue and into nails, and its recognized fungicidal action are the most likely features responsible for its success in the treatment of chronic fungal diseases, including those with immunological defects. Terbinafine is well tolerated, particularly when compared with other available systemic antifungal drugs.
特比萘芬（兰美抒）是一种抗真菌药物，属于烯丙胺类药物，最近已可用于临床。本文报告了过去5年中对2500例患者口服特比萘芬进行全身治疗评估期间出现的四个特点。这些特点包括：（i）特比萘芬在皮肤、毛发和指甲组织中的分布；（ii）用于慢性足癣和甲癣的短期治疗；（iii）用于经常伴有局部或全身性免疫缺陷的严重感染患者；（iv）该药物的耐受性和安全性。特比萘芬扩散到增厚的慢性感染组织和指甲中，以及其公认的杀真菌作用，最有可能是其成功治疗慢性真菌病（包括伴有免疫缺陷的真菌病）的原因。特比萘芬耐受性良好，尤其是与其他现有的全身抗真菌药物相比。
